Connect with us

Health

Study Shows Significant Reduction in Triglycerides in Patients at High Risk for Acute Pancreatitis Through Novel Monoclonal Antibody – Newswise

The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancre

Published

on

Article feature image

Contact: Ilana NikraveshMount Sinai Press Office (347) 852-3382                   [email protected]
(New York, NY – May 16, 2021) – The investigational drug evinacumab reduced triglycerides in patients with severe hypertriglyceridemia (sHTG) and a history of hospitalizations for acute pancreatitis in a phase 2 global study led by Mount Sinai. The fully human monoclonal antibody produced sustained reductions in triglyceride levels of up to 82 percent, depending on the patient’s genotype, while also…

Click here to view the original article.

You might also like ...

Article feature image
Over-40s in Scotland urged to book second COVID jab as soon as possible – Yahoo Philippines News
A physicist from Paimpol was shortlisted for the European Inventor Prize – Awani Review
Article feature image
Australia’s Victoria state expects further easing of COVID-19 curbs … – Latest Tweet by Reuters – LatestLY